Geron (GERN) Restructuring Costs (2012 - 2026)

Geron (GERN) posted Restructuring Costs of -$394000.0 for Q1 2026, down 860.98% sequentially from -$41000.0 in Q3 2015.

Geron (GERN) Restructuring Costs (2012 - 2026) Analysis & Trends

Geron has reported Restructuring Costs for 4 years, with the latest figure at -$394000.0 in Q1 2026.

Quarterly Restructuring Costs changed N/A year-over-year to -$394000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$435000.0 (down 148.33% YoY) and the FY2025 annual result came in at $17.0 million, changed N/A from the prior year.
Restructuring Costs fell to -$394000.0 in Q1 2026 per GERN's latest filing, from -$41000.0 in the prior quarter.
Over five years, Restructuring Costs peaked at -$394000.0 in Q1 2026 and troughed at -$394000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Geron	1.04 Mn	-299.81 Mn	-

Download Data